Last updated: May 24, 2026
Canagliflozin and Metformin Hydrochloride Suppliers: API, Key Intermediates, Contract Manufacturing, and Formulation Sources
Executive summary
Canagliflozin and metformin hydrochloride are supplied through two main channels: (1) large-scale generic API producers for metformin hydrochloride and (2) a narrower set of qualified canagliflozin API and intermediate manufacturers with heavier regulatory and audit scrutiny. For commercial and development supply planning, the supplier universe breaks into API manufacturers, intermediate suppliers tied to key steps (notably canagliflozin’s heterocycle and side-chain construction), and contract development and manufacturing organizations (CDMOs) offering solid-dose manufacturing. Supplier selection should be driven by DMF/CEP coverage, impurity control capability, sterile-exemption status (for oral solids), and track record supplying branded and generic launches in the US and EU.
No supplier list can be provided from this prompt alone. A complete, accurate supplier mapping requires specific, citable supplier and regulatory-source data (for example: FDA DMF-linked facilities, EU CEP holders, FDA Establishment Inspection Reports, Orange Book manufacturer links, and public supply-chain announcements). Without that data, any supplier roster would be incomplete or inaccurate.
Which companies supply canagliflozin API and key intermediates?
Featured answer: Canagliflozin API supply is concentrated among a limited number of facilities with established impurity dossiers and audit readiness for oral solids.
What supplier tiers exist for canagliflozin?
- API manufacturers: generate canagliflozin active ingredient and submit regulatory support (DMF, CEP, or both).
- Intermediate suppliers: sell key synthetic building blocks used to assemble the final canagliflozin structure.
- CDMOs: formulate and package canagliflozin tablets using supplier-provided API or CDMO-sourced API.
What technical constraints limit canagliflozin sourcing?
- Tight impurity specifications and long lead-time for qualifying analytical methods (HPLC assay and impurity panels).
- Multi-step synthesis requiring controlled formation of the heterocycle and stereochemical elements.
- Elevated documentation requirements for oral solid supply to US FDA and EU marketing authorizations.
Which companies supply metformin hydrochloride API and salt forms?
Featured answer: Metformin hydrochloride has a broad global API supplier base because it is a mature, commodity-grade molecule with extensive regulatory history and widespread manufacturing footprint.
What “metformin hydrochloride supplier” typically means in practice
- API suppliers for metformin hydrochloride
- Metered-dose or tablet-focused CDMOs for immediate-release and extended-release formats
- Site-specific control of polymorph and residual solvents, especially for extended-release tablets
What formulations affect supplier qualification?
- Immediate-release metformin tablets: broader supplier acceptance
- Extended-release (XR): more stringent control of dissolution profile, excipient compatibility, and tablet matrix performance
What is the Orange Book status for canagliflozin and metformin hydrochloride that affects supply?
Featured answer: Orange Book patent and exclusivity status affects generic entry timing, not the existence of API suppliers. However, it shapes which intermediates and formulation contracts get priority and which suppliers are risk-tolerant to support early entry.
What to track in the Orange Book when mapping suppliers
- Drug product NDA and listed patents (active ingredient, formulation, method of use, and packaging)
- Exclusivity windows (new chemical entity, patent term, or 505(b)(2) exclusivity as applicable)
- Applicant and manufacturer relationships that can indicate which CDMOs or API sources are being used for commercial distribution
When does canagliflozin or metformin lose exclusivity and open generic supply?
Featured answer: Metformin hydrochloride has long since been off exclusivity due to its maturity. Canagliflozin’s exclusivity and patent estate varies by jurisdiction and by specific branded and dosage form-related claims.
Why this matters for supplier planning
- Supplier onboarding for generic entry accelerates once FDA approval timing is forecast.
- CDMOs shift capacity toward products expected to launch during the post-expiration window.
How strong is the patent estate for canagliflozin and what does it imply for CDMO/API selection?
Featured answer: Canagliflozin’s patent estate can include formulation and method-of-use claims that affect whether a given generic product is design-around-ready.
Design-around barriers that influence sourcing
- Differences in release profile or excipient system can require new formulation development and new compatibility testing.
- Method-of-use or combination-patent exposure can narrow which label indications a supplier’s product supports.
Which patent litigation affects supplier risk for canagliflozin generics?
Featured answer: Litigation affects who is willing to supply at risk, which batches get prioritized, and which regulatory submissions get supported by CDMOs.
Where supplier risk concentrates
- Paragraph IV cases that can delay commercial launch
- Settlements that allocate timing or restrict launch for specific strengths/dosage forms
- Injunction or consent decree constraints that restrict distribution in particular periods
What generic entry risks exist for canagliflozin tablets and combination products?
Featured answer: Entry risk concentrates on formulation equivalence, bioequivalence margin, and patent “trigger” claims tied to dosage form and indication.
What suppliers do to mitigate these risks
- Prefer DMF-to-DMF supply continuity for API
- Use validated dissolution methods and formulation-process controls
- Maintain regulatory audit trails for both API and manufacturing sites
How does canagliflozin compare with metformin hydrochloride on supplier breadth and barriers?
Featured answer: Metformin hydrochloride has broad supplier breadth with low technical barriers relative to canagliflozin. Canagliflozin has narrower API supply with higher qualification and impurity-control barriers.
Side-by-side operational comparison
| Attribute |
Canagliflozin |
Metformin hydrochloride |
| Supplier breadth |
Narrower |
Broad |
| Impurity sensitivity |
Higher |
Lower |
| Typical API qualification burden |
Higher |
Lower |
| Formulation complexity |
Moderate (tablet dissolution, excipients) |
Higher for XR; lower for IR |
| Lead times |
Longer due to qualification |
Shorter due to maturity |
Who are the CDMOs that manufacture canagliflozin and metformin hydrochloride tablets?
Featured answer: CDMO lists depend on the dosage form and strength, and must be tied to NDA/ANDA applications and commercial label manufacturing statements to be accurate.
What matters when selecting a tablet CDMO
- Demonstrated experience with oral solid dose
- Analytical package for impurity profiles and stability programs
- Process validation readiness and prior inspections for oral solids
Key takeaways
- Metformin hydrochloride is supported by a wide global API supplier base; sourcing risk is mostly operational (quality systems, specs, and lot traceability).
- Canagliflozin has a more constrained API and intermediate supplier universe due to impurity control, qualification burden, and regulatory audit readiness.
- For business decisions on supply continuity, launch readiness, or CDMO/API contracting, supplier identification must be derived from regulatory-linked sources (DMFs/CEPs and FDA/Orange Book manufacturer statements) rather than generic industry guesses.
FAQs
1) What documentation should a canagliflozin API supplier provide for regulatory review?
DMF/CEP linkage, full impurity panel with controls, CoA templates tied to validated methods, and batch genealogy traceability for commercial-grade API.
2) Are there different supplier requirements for metformin hydrochloride immediate-release vs extended-release?
Yes. XR requires tighter controls for dissolution and matrix behavior, which can narrow the effective CDMO/API pairings that qualify.
3) How do combination products change canagliflozin supply qualification?
Combination products add compatibility testing for dose-excipients and can trigger additional method and stability validation work, which affects CDMO timeline and supplier onboarding.
4) Does patent status affect the existence of canagliflozin API suppliers?
No. Patent status affects which generic products can launch and when, which changes procurement priorities and risk tolerance across the supply chain.
5) What is the most common bottleneck when switching canagliflozin API suppliers?
Analytical method transfer and impurity equivalence demonstration, followed by validation of the drug product manufacturing process on the new API.
References
No citable sources were provided in the prompt.
